Home World New research: These three vaccines are difficult to resist Omicron | Antibody | Pfizer | Sinopharm

New research: These three vaccines are difficult to resist Omicron | Antibody | Pfizer | Sinopharm

by admin

[Epoch Times December 18, 2021](Epoch Times reporter Xu Jian comprehensive report) According to the latest authoritative research, the US Johnson & Johnson, Sinopharm, and Russia’s Sputnik V vaccine were produced against the Omicron variant Little or no neutralizing antibodies are produced.

Bloomberg reported on December 17 that the research was jointly conducted by Swiss Humabs Biomed SA, a subsidiary of Vir Biotechnology of the United States, and the University of Washington. Humabs BioMed SA has a proprietary technology that can quickly isolate and develop natural selection through the human immune system. antibody.

The researchers selected the Omicron variant of the Chinese Communist virus (new crown virus, COVID-19) to compare with the original virus strain found in China, and experimented with the six currently widely used vaccines (Pfizer, Modena, AstraZeneca, Johnson & Johnson, Johnson & Johnson). Sinopharm and Sputnik) and different therapeutic drugs.

The test found that Pfizer, Moderna, and AstraZeneca vaccines still have a certain neutralizing ability to Omicron, but their ability to antibody against the original strain is greatly reduced.

The Sinopharm, Johnson & Johnson and Sputnik vaccines are very poorly effective against Omicron. Of the 13 people who received two doses of the Sinopharm vaccine, only 3 developed neutralizing antibodies against Omicron. Only 1 out of 12 people who received the Johnson & Johnson vaccine produced antibodies. Among the 11 people who were fully vaccinated with Sputnik, none developed Omicron neutralizing antibodies.

This finding is consistent with other studies, which means that the vaccine has clearly lost its protective effect. Research from the University of Hong Kong this week showed that two doses of Sinovac vaccine could not protect against Omicron at all.

The study also found that people who have been infected with the virus and have received two doses of Pfizer vaccine have the strongest resistance, and their antibody levels have only dropped by five times, while those who have received two doses of Pfizer vaccine but have no history of infection The level of antibodies dropped 44 times.

Humabs BioMed SA also compared drugs for the treatment of COVID-19 and found that Sotrovimab, a drug jointly developed by GlaxoSmithKline (GSK) and Vir Biotech of the United States, was three times less effective for Omicron compared to the original strain.

But this is not the worst. When faced with the Omicron variant, the monoclonal antibody produced by Regeneron and the research monoclonal antibody drug from Eli Lilly These treatment methods have completely lost the ability to neutralize.

Bloomberg reported that from the real data in South Africa, it can be seen that since the emergence of the Omicron variant last month, the effect of Pfizer’s vaccine has been unsatisfactory, which further confirms the ability of this new mutant strain to evade the vaccine.

The infection rate of the new Omicron variant is currently 70 times faster than that of the deadly Delta variant. Less than a month after it was first discovered in Southern Africa, it has rapidly spread to at least about 77 countries.

Editor in charge: Lin Yan#

.

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy